Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$1.22
-0.8%
$1.57
$1.20
$8.70
$19.33M1.2973,883 shs56,221 shs
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$1.19
-1.7%
$1.28
$0.57
$1.70
$54.28M1.22272,822 shs348,448 shs
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$1.99
-0.5%
$1.93
$0.90
$3.49
$77.61M1.63197,143 shs113,946 shs
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$0.28
-6.6%
$0.38
$0.27
$1.10
$12.85M2.96107,117 shs51,554 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-0.81%-3.17%-19.21%-36.13%-83.06%
AVROBIO, Inc. stock logo
AVRO
AVROBIO
-1.65%-2.46%-2.46%-9.85%+34.46%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-0.50%+4.74%+9.34%-12.33%+12.43%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-6.05%-9.39%-31.15%-31.57%-72.73%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.146 of 5 stars
3.53.00.00.00.60.00.6
AVROBIO, Inc. stock logo
AVRO
AVROBIO
1.0438 of 5 stars
3.03.00.00.00.01.70.6
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3.5143 of 5 stars
3.55.00.00.03.24.20.0
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
2.4657 of 5 stars
3.54.00.00.02.60.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
3.00
Buy$19.801,522.95% Upside
AVROBIO, Inc. stock logo
AVRO
AVROBIO
2.00
Hold$2.0068.07% Upside
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
3.00
Buy$6.67235.01% Upside
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3.00
Buy$6.002,035.99% Upside

Current Analyst Ratings

Latest APTO, CGTX, AVRO, and SNTI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/3/2024
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$5.00
3/28/2024
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
3/27/2024
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00
3/27/2024
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$9.00
2/1/2024
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$12.00 ➝ $5.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/A($0.19) per shareN/A
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/A$0.28 per share4.19$2.13 per shareN/A
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/A$0.76 per shareN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$2.56M5.02N/AN/A$1.50 per share0.19

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)
AVROBIO, Inc. stock logo
AVRO
AVROBIO
$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$25.79M-$0.86N/AN/AN/AN/A-83.48%-63.07%5/2/2024 (Estimated)
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$71.06M-$1.60N/AN/A-2,692.82%-74.59%-48.22%5/14/2024 (Estimated)

Latest APTO, CGTX, AVRO, and SNTI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$1.48-$1.44+$0.04-$1.44N/AN/A
3/26/2024Q4 2023
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.38-$0.27+$0.11-$0.27N/AN/A
3/21/2024Q4 2023
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/A-$0.42-$0.42-$0.42N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/A
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/AN/AN/AN/AN/A
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/A
0.78
0.78
AVROBIO, Inc. stock logo
AVRO
AVROBIO
N/A
15.78
15.78
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/A
3.37
3.37
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/A
5.62
5.62

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
26.62%
AVROBIO, Inc. stock logo
AVRO
AVROBIO
62.63%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
43.35%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
25.73%

Insider Ownership

CompanyInsider Ownership
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
9.53%
AVROBIO, Inc. stock logo
AVRO
AVROBIO
9.20%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
23.80%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
12.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
3115.72 million14.22 millionNo Data
AVROBIO, Inc. stock logo
AVRO
AVROBIO
1344.86 million40.73 millionOptionable
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2539.00 million29.72 millionNot Optionable
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
4845.76 million40.04 millionNot Optionable

APTO, CGTX, AVRO, and SNTI Headlines

SourceHeadline
Senti Biosciences (NASDAQ:SNTI)  Shares Down 8.7% Senti Biosciences (NASDAQ:SNTI) Shares Down 8.7%
americanbankingnews.com - April 23 at 3:00 AM
Senti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
finanznachrichten.de - March 23 at 5:22 PM
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsSenti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
globenewswire.com - March 21 at 4:05 PM
Senti Biosciences Stock (NASDAQ:SNTI), Guidance and ForecastSenti Biosciences Stock (NASDAQ:SNTI), Guidance and Forecast
benzinga.com - February 4 at 7:36 PM
Senti Biosciences, Inc.: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramSenti Biosciences, Inc.: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
finanznachrichten.de - January 8 at 7:36 AM
Senti Biosciences to Cut Workforce by 37% to Focus on Potential Cancer TreatmentSenti Biosciences to Cut Workforce by 37% to Focus on Potential Cancer Treatment
marketwatch.com - January 5 at 8:33 PM
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramSenti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
finance.yahoo.com - January 5 at 8:33 PM
Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?
finance.yahoo.com - December 22 at 12:31 PM
Senti Bio : FDA Clears IND Application For SENTI-202 For Treatment Of R/R Hematologic MalignanciesSenti Bio : FDA Clears IND Application For SENTI-202 For Treatment Of R/R Hematologic Malignancies
markets.businessinsider.com - December 22 at 7:31 AM
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaSenti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
finance.yahoo.com - December 22 at 7:31 AM
Senti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesSenti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
finanznachrichten.de - November 24 at 8:31 AM
Senti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesSenti Bio Announces Third Quarter 2023 Results and Pipeline Updates
finance.yahoo.com - November 13 at 5:04 PM
Senti Biosciences Inc SNTISenti Biosciences Inc SNTI
morningstar.com - November 11 at 1:25 PM
Senti, Celest take liver cancer cell therapy to China in $156M biobucks dealSenti, Celest take liver cancer cell therapy to China in $156M biobucks deal
fiercebiotech.com - November 9 at 6:36 PM
Off-the-shelf CAR-NK cell therapy to be developed in ChinaOff-the-shelf CAR-NK cell therapy to be developed in China
thepharmaletter.com - November 9 at 1:36 PM
Recent Insider Activity Could Benefit Senti Biosciences Inc. (SNTI)Recent Insider Activity Could Benefit Senti Biosciences Inc. (SNTI)
knoxdaily.com - November 8 at 8:13 PM
Why Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?Why Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?
msn.com - November 7 at 1:54 PM
Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?
msn.com - November 7 at 8:53 AM
Why Is Senti Biosciences (SNTI) Stock Up 140% Today?Why Is Senti Biosciences (SNTI) Stock Up 140% Today?
msn.com - November 7 at 8:53 AM
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in ChinaSenti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
finance.yahoo.com - November 6 at 7:39 PM
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual MeetingSenti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
finance.yahoo.com - October 31 at 1:59 PM
Gene and cell therapy startup GeneFab takes over Senti Biosciences Alameda manufacturing facilityGene and cell therapy startup GeneFab takes over Senti Biosciences' Alameda manufacturing facility
bizjournals.com - October 9 at 8:46 PM
Taking a look at what insiders are doing to gauge the Senti Biosciences Inc. (SNTI)’s directionTaking a look at what insiders are doing to gauge the Senti Biosciences Inc. (SNTI)’s direction
knoxdaily.com - October 5 at 3:22 PM
Shanti Overseas India Ltd (SNTI)Shanti Overseas India Ltd (SNTI)
investing.com - September 27 at 6:28 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptose Biosciences logo

Aptose Biosciences

NASDAQ:APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
AVROBIO logo

AVROBIO

NASDAQ:AVRO
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Cognition Therapeutics logo

Cognition Therapeutics

NASDAQ:CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Senti Biosciences logo

Senti Biosciences

NASDAQ:SNTI
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.